Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.48 |
| ▸ | NOS1 | P29475 | 2/20 | 0.48 |
| ▸ | NOS2 | P35228 | 2/20 | 0.48 |
| ▸ | GNAO1 | P09471 | 7/20 | 0.46 |
| ▸ | GNAI3 | P08754 | 6/20 | 0.46 |
| ▸ | GNAI1 | P63096 | 6/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23572092 | 0.88 | NOS3 (0.46) | NOS3NOS1NOS2GNAO1GNAI3 | |
| SCHEMBL22837641 | 0.87 | NOS3 (0.47) | NOS3NOS1NOS2GNAO1GNAI3 | |
| SCHEMBL22793894 | 0.85 | GNAO1 (0.47) | NOS3NOS1NOS2GNAO1GNAI3 | |
| SCHEMBL4110445 | 0.84 | GNAO1 (0.48) | NOS3NOS1NOS2GNAO1GNAI3 | |
| SCHEMBL23696231 | 0.82 | PIK3CD (0.47) | NOS3NOS1NOS2GNAO1GNAI3 | |
| SCHEMBL14344936 | 0.81 | NOS3 (0.35) | NOS3NOS1NOS2KMT2A | |
| SCHEMBL20160778 | 0.81 | NOS3 (0.35) | NOS3NOS1NOS2KMT2A | |
| SCHEMBL14344871 | 0.81 | SLC18A3 (0.40) | NOS3NOS1NOS2KMT2A | |
| SCHEMBL25122780 | 0.80 | GLB1 (0.48) | NOS3NOS1NOS2GNAO1GNAI3 | |
| SCHEMBL23696447 | 0.80 | GNAO1 (0.39) | NOS3NOS1NOS2GNAO1GNAI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023192578-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023192586-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230295180-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295180-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| WO-2023076161-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2022147465-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| WO-2022125790-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022125804-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| WO-2021127283-A2 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021127190-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021127278-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021011868-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
| WO-2020264490-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020264499-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295180-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | NOS3 4447/4885NOS1 4237/4885NOS2 4373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.